A 3-part Open-label Study Assessing Safety, Tolerability, Pharmacokinetic and -Dynamic Profiles, and Efficacy of Tofacitinib in Young Adults From Age 18 to 45 With Moderate to Severe Skin Involvement Due to Lupus
Phase of Trial: Phase I/II
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Tofacitinib (Primary)
- Indications Cutaneous lupus erythematosus; Systemic lupus erythematosus
- Focus Pharmacokinetics
- 31 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2020.
- 11 Jul 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2018.
- 22 Sep 2017 New trial record